Brokerages Set Tilray Inc (NASDAQ:TLRY) PT at $5.08
Brokerages Set Tilray Inc (NASDAQ:TLRY) PT at $5.08
Shares of Tilray Inc (NASDAQ:TLRY – Get Rating) have earned an average rating of "Hold" from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $5.08.
据MarketBeat.com报道,Tilray Inc.(纳斯达克代码:TLRY-GET Rating)的股票在涵盖该股票的12家券商的平均评级为“持有”。两名投资分析师对该股的评级为卖出建议,五名分析师给出了持有建议,一名分析师给出了买入建议。在过去一年更新该股覆盖范围的券商中,1年目标价的平均水平为5.08美元。
A number of research analysts have issued reports on TLRY shares. Sanford C. Bernstein started coverage on Tilray in a research note on Tuesday, November 1st. They issued a "market perform" rating and a $3.90 price objective for the company. Haywood Securities reduced their price objective on Tilray to $3.50 in a research note on Thursday, October 13th. Alliance Global Partners dropped their price target on Tilray from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Monday, January 9th. Finally, Cantor Fitzgerald upped their price target on Tilray from $4.15 to $4.50 and gave the company a "neutral" rating in a research report on Monday, October 10th.
一些研究分析师已经发布了关于TLRY股票的报告。桑福德·C·伯恩斯坦于11月1日星期二在一份研究报告中开始对Tilray进行报道。他们对该公司的评级为“市场表现”,目标价为3.9美元。海伍德证券在10月13日星期四的一份研究报告中将Tilray的目标价下调至3.50美元。Alliance Global Partners在1月9日周一的一份研究报告中将Tilray的目标价从4.00美元下调至3.00美元,并将该股的评级定为“中性”。最后,康托·菲茨杰拉德在10月10日星期一的一份研究报告中将Tilray的目标价从4.15美元上调至4.50美元,并给予该公司中性评级。
Insiders Place Their Bets
内部人士下注
In other news, Director Brendan Kennedy sold 350,000 shares of the firm's stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $3.78, for a total value of $1,323,000.00. Following the completion of the transaction, the director now owns 6,224,196 shares in the company, valued at approximately $23,527,460.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.54% of the company's stock.
在其他新闻方面,董事布兰登·肯尼迪在11月7日星期一的一笔交易中出售了350,000股该公司股票。这只股票的平均售价为3.78美元,总价值为1,323,000.00美元。交易完成后,董事现在拥有该公司6224,196股,价值约23,527,460.88美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在以下网址获得美国证券交易委员会网站。公司内部人士持有该公司2.54%的股份。
Institutional Inflows and Outflows
机构资金流入和流出
Tilray Price Performance
磁贴纸盘性价比
Shares of TLRY opened at $3.20 on Monday. Tilray has a 52-week low of $2.52 and a 52-week high of $9.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.35 and a current ratio of 1.91. The business's 50 day moving average price is $3.22 and its two-hundred day moving average price is $3.44. The firm has a market cap of $1.97 billion, a PE ratio of -3.05 and a beta of 2.68.
周一,TLRY的股价开盘报3.20美元。Tilray的52周低点为2.52美元,52周高点为9.08美元。该公司的负债权益比率为0.09,速动比率为1.35,流动比率为1.91。该业务的50日移动均线价格为3.22美元,200日移动均线价格为3.44美元。该公司市值19.7亿美元,市盈率为-3.05,贝塔系数为2.68。
Tilray (NASDAQ:TLRY – Get Rating) last released its quarterly earnings data on Monday, January 9th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $144.10 million for the quarter, compared to the consensus estimate of $157.21 million. Tilray had a negative net margin of 89.96% and a negative return on equity of 5.10%. The business's revenue for the quarter was down 7.1% compared to the same quarter last year. On average, equities analysts anticipate that Tilray will post -0.34 EPS for the current year.
纳斯达克(Tilray:TLRY-GET Rating)上一次发布季度收益数据是在1月9日星期一。该公司公布本季度每股收益(0.06美元),低于普遍预期的(0.05美元)和(0.01美元)。该公司本季度营收为1.441亿美元,而市场普遍预期为1.5721亿美元。Tilray的净利润率为负89.96%,股本回报率为负5.10%。与去年同期相比,该业务本季度的收入下降了7.1%。股票分析师平均预计,Tilray本年度每股收益将为0.34美元。
About Tilray
关于Tilray
(Get Rating)
(获取评级)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Tilray,Inc.从事医用大麻的研究、种植、加工和分销。该公司在阿根廷、澳大利亚、加拿大、智利、克罗地亚、塞浦路斯、捷克共和国、德国、新西兰和南非销售其产品。Tilray,Inc.总部设在加拿大纳奈莫。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Tilray (TLRY)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取StockNews.com关于Tilray的研究报告(TLRY)
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet盈利节节攀升,增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Tilray Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tilray和相关公司的最新新闻和分析师评级的每日简要摘要。